Redhawk Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Redhawk Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-67,778	Closed	-$1.47M	–	346
2025 Q2	$1.47M	Buy	67,778 +13,407	+25%	+$316K	0.18%	111
2025 Q1	$1.32M	Sell	54,371 -6,638	-11%	-$149K	0.18%	103
2024 Q4	$1.27M	Buy	+61,009	New	+$1.31M	0.17%	105
2023 Q2	–	Sell	-29,874	Closed	-$495K	–	208
2023 Q1	$495K	Sell	29,874 -1,636	-5%	-$27K	0.17%	109
2022 Q4	$586K	Buy	+31,510	New	+$485K	0.23%	104

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Redhawk Wealth Advisors's CPRX Position: Q3 2025 in Review

Redhawk Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 67,778 shares — an estimated $1.47M sold.

Redhawk Wealth Advisors first reported a position in CPRX in Q4 2022 and held it in 5 quarters. The position peaked at $1.47M in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

Redhawk Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Redhawk Wealth Advisors sold 67,778 Catalyst Pharmaceutical shares in Q3 2025, an estimated $1.47M.
Redhawk Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 5 quarters.
Redhawk Wealth Advisors's Catalyst Pharmaceutical position peaked at $1.47M in Q2 2025.
360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Redhawk Wealth Advisors's 13F filing for Q3 2025, filed 9 Oct 2025.